The Association between Low-Grade Proteinuria and Adverse Kidney Outcomes in IgA Nephropathy
Rattachement africain : jp, au. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
KEY POINTS: Systematic review/meta-analysis of 23 studies (15,289 patients) quantified prognostic effect of low-grade proteinuria in IgA nephropathy. Low-grade proteinuria (0.5-1.0 g/d) linked to higher kidney risk (hazard ratio, 1.73-2.87) and faster eGFR decline (-1.02 ml/min per year). Long-term suppression below 0.5 g/d should be a key therapeutic goal, supporting current IgA nephropathy clinical guidelines. BACKGROUND: Overt proteinuria (>1.0 g/d) is a well-established risk factor for kidney disease progression in IgA nephropathy. However, recent evidence suggests that even low-grade proteinuria, typically defined as 0.5-1.0 g/d, may be clinically significant. The prognostic effect of low-grade proteinuria has not been systematically evaluated. METHODS: We conducted a systematic review and meta-analysis to evaluate the association between low-grade proteinuria and adverse kidney outcomes in patients with IgA nephropathy. A systematic literature search was performed on PubMed and Web of Science. Eligible studies included those reporting on kidney outcomes such as eGFR decline, kidney failure, or eGFR slope in relation to low-grade proteinuria measured either at baseline or during follow-up ( e.g ., time-averaged proteinuria). Data were synthesized using random-effects meta-analysis. The protocol was registered in the Open Science Framework REGISTRIES ( https://osf.io/5dfqr ). RESULTS: A total of 23 studies ( N =15,289) met the inclusion criteria, of which 15 contributed to at least one meta-analysis. Baseline low-grade proteinuria was significantly associated with an increased risk of adverse kidney outcomes compared with proteinuria below 0.5 g/d (pooled hazard ratio, 1.73; 95% confidence interval [CI], 1.36 to 2.20; nine studies). Similarly, low-grade time-averaged proteinuria was associated with a higher risk of kidney outcomes (pooled hazard ratio, 2.87; 95% CI, 1.48 to 5.56; seven studies) and a significantly steeper annual decline in eGFR (mean difference, -1.02 ml/min per 1.73 m 2 per year; 95% CI, -1.60 to -0.45; four studies). Subgroup analyses and leave-one-out sensitivity analyses were consistent with the overall findings. CONCLUSIONS: Low-grade proteinuria, whether assessed at baseline or over time, is an important predictor of kidney disease progression in patients with IgA nephropathy. These results reinforce recent clinical guidelines recommending proteinuria control under 0.5 g/d. Long-term suppression of proteinuria should be considered a key therapeutic goal in IgA nephropathy.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- The Association between Low-Grade Proteinuria and Adverse Kidney Outcomes in IgA Nephropathy
- Date Crossref
- 12/12/2025
- Éditeur
- Ovid Technologies (Wolters Kluwer Health)
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Jikei University School of Medicine Department of Internal Medicine pays non établi dans la noticeUniversité ou école supérieure
-
UNSW Sydney pays non établi dans la noticeUniversité ou école supérieure
-
The George Institute for Global Health Renal and Metabolic Division pays non établi dans la noticeStructure de recherche
-
Nara Medical University Department of Nephrology pays non établi dans la noticeUniversité ou école supérieure
-
Prince of Wales Hospital Department of Nephrology pays non établi dans la noticeÉtablissement de santé
-
University of New South Wales The George Institute for Global Health pays non établi dans la noticeUniversité ou école supérieure
Department of Internal Medicine — Jikei University School of Medicine, UNSW Sydney et Renal and Metabolic Division — The George Institute for Global Health, avec 3 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.